Fulgent Genetics, Inc.
FLGT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1 | $1 | $1 | $3 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1 | $1 | $1 | $3 |
| Revenue | $0 | $0 | $1 | $1 |
| % Growth | -2% | -53.3% | -37.6% | – |
| Gross Profit | $0 | $0 | $0 | $1 |
| % Margin | 37.8% | 36.1% | 59.3% | 78.3% |
| EBITDA | -$0 | -$0 | $0 | $1 |
| % Margin | -17.3% | -51% | 35.2% | 69.2% |
| Net Income | -$0 | -$0 | $0 | $1 |
| % Margin | -15.1% | -58% | 23.2% | 51.1% |
| EPS Diluted | -1.41 | -5.63 | 4.63 | 16.26 |
| % Growth | 75% | -221.6% | -71.5% | – |
| Operating Cash Flow | $0 | $0 | $0 | $1 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | $0 | $0 | $1 |